What do we know about metabolic syndrome in adolescents with PCOS?
Yıl: 2014 Cilt: 15 Sayı: 1 Sayfa Aralığı: 49 - 55 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022
What do we know about metabolic syndrome in adolescents with PCOS?
Öz: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of reproductive-aged women that manifests itself with a variety of features. For this reason, three different diagnostic criteria have been introduced. For adults, the National Institutes of Health Conference (NIH) criteria, which consists of hyperandrogenism and oligo-anovulation, is the most widely used. Symptoms of PCOS usually start with puberty and may overlap with normal pubertal development. Hormonal fluctuations during this period make the diagnosis of PCOS more difficult. Until now, there is no validated diagnostic criteria for PCOS in adolescents. Although menstrual disorders and cosmetic problems are the most com- mon complaints of adolescents with PCOS, patients should also be evaluated for the potential risk for insulin resistance, obesity, subclinical atherosclerosis, diabetes, metabolic syndrome and cardiovascular disease. Obesity is the most prominent predictor of metabolic syndrome. As the incidence of obesity is increasing both in childhood and adolescence, governments will be faced with a social and economic burden in the future. Adolescents with PCOS are more obese than normal adolescents and have an increased risk of metabolic syndrome. It is suggested that abdominal adiposity increases the risk of metabolic syndrome by inducing various cytokine secretions. Although there is no consensus on metabolic syndrome criteria in the adolescent period, International Diabetes Federation (IDF) criteria may be used for children older than 10 years. Various clinical and metabolic markers are investigated for the prediction of metabolic syndrome in the literature. Waist circumference, serum triglycerides and androgens are the suspected predictors of metabolic syndrome. The prevention of abdominal adiposity and the early diagnosis of PCOS in adolescence should be the main target for the prevention of metabolic syndrome. Clinicians should investigate adoles- cents with PCOS for metabolic and cardiovascular risks and take preventive action. A Mediterranean diet, low in fat and high in fruits and veg- etables, along with moderate-intensity exercise and smoking cessation are the recommended interventions for especially obese adolescents with PCOS. Metformin may be the treatment of choice when lifestyle modifications are ineffective.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Stein IF. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181.
- Dilbaz B, Ozkaya E, Cinar M, Cakir E, Dilbaz S. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 2011; 39: 272-7. [CrossRef]
- Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-88. [CrossRef]
- Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-92. [CrossRef]
- Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203: 201.e1-5.
- Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syn- drome. Lancet 2007; 370: 685-97. [CrossRef]
- Bonny AE, Appelbaum H, Connor EL, Cromer B, DiVasta A, Gomez- Lobo V, et al. Clinical variability in approaches to polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2012; 25: 259-61. [CrossRef]
- Hardy TSE, Norman RJ. Diagnosis of adolescent polycystic ovary syndrome. Steroids. 2013; 78: 751-4. [CrossRef]
- Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phe- notype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27: 3067-73. [CrossRef]
- Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clini- cal, and genetic association studies. J Clin Endocrinol Metab 2006; 91: 1660-6. [CrossRef]
- Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006; 29: 278-85. [CrossRef]
- Abbott DH, Dumesic DA, Franks S. Developmental origin of poly- cystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174: 1-5. [CrossRef]
- Barbieri RL, Hornstein MD. Hyperinsulinemia and ovarian hyper- androgenism. Cause and effect. Endocrinol Metab Clin North Am 1988; 17: 685-703.
- Omar HA, Logsdon S, Richards J. Clinical profiles, occurrence, and management of adolescent patients with HAIR-AN syndrome. Scientific World Journal 2004; 4: 507-11. [CrossRef]
- Kaltsas GA, Mukherjee JJ, Jenkins PJ, Satta MA, Islam N, Monson JP et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999; 84: 2731-5. [CrossRef]
- Battaglia C, Regnani G, Mancini F, Iughetti L, Flamigni C, Venturoli S. Polycystic ovaries in childhood: a common finding in daugh- ters of PCOS patients. A pilot study. Hum Reprod 2002; 17: 771-6. [CrossRef]
- Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 1275-83. [CrossRef]
- Pugeat M. Genetics of the polycystic ovarian syndrome and thera- peutic perspectives. Rev Med Chir Soc Med Nat Iasi 2000; 104: 11-9.
- Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic fea- tures of polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4297-300. [CrossRef]
- Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar- Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the poly- cystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-49. [CrossRef]
- Mosca L. Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 2007; 10: 19-25. [CrossRef]
- Teede H, Ng S, Hedger M, Moran L. Follistatin and activins in poly- cystic ovary syndrome: relationship to metabolic and hormonal markers. Metabolism 2013; 62: 1394- 400. [CrossRef]
- Knight PG, Satchell L, Glister C. Intra-ovarian roles of activins and inhibins. Mol Cell Endocrinol 2012; 359: 53-65. [CrossRef]
- Sjöholm A, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006; 22: 4-10. [CrossRef]
- Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003; 46: 1594-603. [CrossRef]
- Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53. [CrossRef]
- Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrøm V, Flyvbjerg A, Hermann AP Evaluation of metabolic risk markers in poly- cystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006; 155: 337-45. [CrossRef]
- Panidis D, Farmakiotis D, Koliakos G, Rousso D, Kourtis A, Katsikis I, et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod 2005; 20: 2127-32. [CrossRef]
- Ersan F, Arslan E, Çorbacıoğlu Esmer A, Aydın S, Gedikbaşı A, Gedikbaşı A, Alkış İ, Ark C. Prediction of metabolic syndrome in women with polycystic ovary syndrome. J Turk Ger Gynecol Assoc 2012; 13: 178-183. [CrossRef]
- Kale-Gurbuz T, Akhan SE, Bastu E, Telci A, Iyibozkurt AC, Topuz S. Adiponectin, leptin and ghrelin levels in obese adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2013; 26: 27-30. [CrossRef]
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. [CrossRef]
- Zimmet P Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306. [CrossRef]
- Çalışkan E, Kılıç T, Bodur H, Zeteroğlu Ş. The frequency of meta- bolic syndrome in women with polycystic ovaries at reproductive ages and comparison of different metabolic syndrome diagnostic criteria. J Turk Ger Gynecol Assoc 2007; 8: 402-7.
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9. [CrossRef]
- Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006; 154: 141-5. [CrossRef]
- Goodman E, Daniels SR, Meigs JB, Dolan LM. Instability in the diag- nosis of metabolic syndrome in adolescents. Circulation 2007; 115: 2316-22. [CrossRef]
- Jolliffe CJ, Janssen I. Development of age-specific adolescent metabolic syndrome criteria that are linked to the Adult Treatment Panel III and International Diabetes Federation criteria. J Am Coll Cardiol 2007; 49: 891-8. [CrossRef]
- Rahmanpour H, Jamal L, Mousavinasab SN, Esmailzadeh A, Azarkhish K. Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents. J Pediatr Adolesc Gynecol 2012; 25: 208-12. [CrossRef]
- Morrison JA, Friedman LA, Harlan WR, Harlan LC, Barton BA, Schreiber GB, Klein DJ. Development of the metabolic syndrome in black and white adolescent girls: a longitudinal assessment. Pediatrics 2005; 116: 1178-82. [CrossRef]
- Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007; 120: 340-5. [CrossRef]
- Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-60. [CrossRef]
- Roe AH, Prochaska E, Smith M, Sammel M, Dokras A. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adoles- cents. J Pediatr 2013; 162: 937-41. [CrossRef]
- Hart R, Doherty DA, Mori T, Huang RC, Norman RJ, Franks S, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 2011; 95: 2347-53. [CrossRef]
- Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N, et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod 2011; 26: 202-13. [CrossRef]
- Amato MC, Guarnotta V, Forti D, Donatelli M, Dolcimascolo S, Giordano C. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syn- drome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. Human Reprod 2013; 28: 1919-28. [CrossRef]
- Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 4780-6. [CrossRef]
- Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose toler- ance test as a screening method. Hum Reprod 2013; 28: 2537-44. [CrossRef]
- Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syn- drome. J Pediatr Adolesc Gynecol 2011; 24: 161-5. [CrossRef]
- Marsh KA, Steinbeck KS, Atkinson FS, Petocz P Brand-Miller JC. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr 2010; 92: 83-92. [CrossRef]
- Stovall DW, Bailey AP Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011; 20: 37-43. [CrossRef]
- Dilbaz B, Çınar M, Özkaya E, Vanlı Tonyalı N, Dilbaz S. Health Related Quality of Life Among Different PCOS Phenotypes of Infertile Women. J Turk Ger Gynecol Assoc 2012; 13: 247-52. [CrossRef]
- Özsoy S. Psychiatric status and approach in polycystic ovary syn- drome and hirsutism. Turkiye Klinikleri J Endocrin-Special Topics 2009; 2: 126-30.
- Tunç S, Tanrıkulu L, Özcan L, Yenicesu O, Akın Su F, Subası B. Psychopathological symptoms in adolescents with hirsutismus. The Journal of Gynecology - Obstetrics and Neonatology 2013; 10: 1518-21.
- Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001; 86: 517-20. [CrossRef]
- Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, et al. Effect of a mediterranean-style diet on endothelial dys- function and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440-6. [CrossRef]
- Zawadzki J, Dunaif A. Diagnostic Criteria for Polycystic Ovary Syndrome: towards a Rational Approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, editors. Polycystic Ovary Syndrome. Blackwell Scientific Publications, Cambridge. 1992.p.377.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25. [CrossRef]
| APA | CIRIK AKDAĞ D, DİLBAZ B (2014). What do we know about metabolic syndrome in adolescents with PCOS?. , 49 - 55. |
| Chicago | CIRIK AKDAĞ Derya,DİLBAZ Berna What do we know about metabolic syndrome in adolescents with PCOS?. (2014): 49 - 55. |
| MLA | CIRIK AKDAĞ Derya,DİLBAZ Berna What do we know about metabolic syndrome in adolescents with PCOS?. , 2014, ss.49 - 55. |
| AMA | CIRIK AKDAĞ D,DİLBAZ B What do we know about metabolic syndrome in adolescents with PCOS?. . 2014; 49 - 55. |
| Vancouver | CIRIK AKDAĞ D,DİLBAZ B What do we know about metabolic syndrome in adolescents with PCOS?. . 2014; 49 - 55. |
| IEEE | CIRIK AKDAĞ D,DİLBAZ B "What do we know about metabolic syndrome in adolescents with PCOS?." , ss.49 - 55, 2014. |
| ISNAD | CIRIK AKDAĞ, Derya - DİLBAZ, Berna. "What do we know about metabolic syndrome in adolescents with PCOS?". (2014), 49-55. |
| APA | CIRIK AKDAĞ D, DİLBAZ B (2014). What do we know about metabolic syndrome in adolescents with PCOS?. Journal of the Turkish-German Gynecological Association, 15(1), 49 - 55. |
| Chicago | CIRIK AKDAĞ Derya,DİLBAZ Berna What do we know about metabolic syndrome in adolescents with PCOS?. Journal of the Turkish-German Gynecological Association 15, no.1 (2014): 49 - 55. |
| MLA | CIRIK AKDAĞ Derya,DİLBAZ Berna What do we know about metabolic syndrome in adolescents with PCOS?. Journal of the Turkish-German Gynecological Association, vol.15, no.1, 2014, ss.49 - 55. |
| AMA | CIRIK AKDAĞ D,DİLBAZ B What do we know about metabolic syndrome in adolescents with PCOS?. Journal of the Turkish-German Gynecological Association. 2014; 15(1): 49 - 55. |
| Vancouver | CIRIK AKDAĞ D,DİLBAZ B What do we know about metabolic syndrome in adolescents with PCOS?. Journal of the Turkish-German Gynecological Association. 2014; 15(1): 49 - 55. |
| IEEE | CIRIK AKDAĞ D,DİLBAZ B "What do we know about metabolic syndrome in adolescents with PCOS?." Journal of the Turkish-German Gynecological Association, 15, ss.49 - 55, 2014. |
| ISNAD | CIRIK AKDAĞ, Derya - DİLBAZ, Berna. "What do we know about metabolic syndrome in adolescents with PCOS?". Journal of the Turkish-German Gynecological Association 15/1 (2014), 49-55. |
